A detailed history of Vanguard Group Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,578,768 shares of BEAM stock, worth $181 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,578,768
Previous 7,164,876 5.78%
Holding current value
$181 Million
Previous $195 Million 28.39%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$23.46 - $45.07 $9.71 Million - $18.7 Million
413,892 Added 5.78%
7,578,768 $250 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $6.19 Million - $10.8 Million
349,906 Added 5.13%
7,164,876 $195 Million
Q3 2023

Nov 14, 2023

SELL
$23.01 - $32.46 $4.49 Million - $6.33 Million
-195,009 Reduced 2.78%
6,814,970 $164 Million
Q2 2023

Aug 14, 2023

BUY
$29.32 - $35.99 $18.3 Million - $22.5 Million
624,488 Added 9.78%
7,009,979 $224 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $3.37 Million - $5.46 Million
111,861 Added 1.78%
6,385,491 $196 Million
Q4 2022

Feb 10, 2023

BUY
$36.73 - $51.6 $3.64 Million - $5.12 Million
99,159 Added 1.61%
6,273,630 $245 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $36.9 Million - $65.2 Million
927,970 Added 17.69%
6,174,471 $294 Million
Q2 2022

Aug 12, 2022

BUY
$29.86 - $62.36 $16 Million - $33.3 Million
534,491 Added 11.34%
5,246,501 $203 Million
Q1 2022

May 13, 2022

BUY
$53.73 - $82.16 $792,248 - $1.21 Million
14,745 Added 0.31%
4,712,010 $270 Million
Q4 2021

Feb 14, 2022

BUY
$68.02 - $99.06 $12.3 Million - $17.9 Million
180,565 Added 4.0%
4,697,265 $374 Million
Q3 2021

Nov 12, 2021

BUY
$84.37 - $133.6 $91.2 Million - $144 Million
1,081,128 Added 31.47%
4,516,700 $393 Million
Q2 2021

Aug 13, 2021

BUY
$64.12 - $128.71 $220 Million - $442 Million
3,435,572 New
3,435,572 $442 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.68B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.